Podcasts about life sciences

Send us a textIn this episode of the Life Science Success Podcast my guest is Josh Yelen, a CPA, MBA, and the Founder & CEO of Function, a strategic financial leadership and bookkeeping services company that supports businesses across various industries, including life sciences. With over two decades of experience in operations, accounting, finance, and sales, Josh is also a co-founder of Venture Forward Capital, where he supports early-stage entrepreneurs in building disruptive companies.00:00 Introduction to Life Science Success Podcast00:40 Join Our Free School Community01:41 Introducing Our Guest: Josh Yelen02:10 Josh Yelen's Professional Journey04:30 The Birth of Venture Forward Capital and Function09:05 Function's Unique Approach to Financial Services14:55 Challenges in Biotech and Pharma20:40 Trends Shaping the Future of Biotech29:19 Firing the Biggest Client and Growing the Business29:46 Innovative Use of AI in Business30:53 Aligning Company Goals with OKRs32:45 The Importance of Focus and Avoiding Distractions36:46 Leadership Advice and Entrepreneurial Challenges39:31 Motivational Videos and Personal Drive45:37 Concerns About AI and the Future of Work50:48 Excitement for the Future and Final Thoughts

Developing a Life Sciences Vision for Ireland: The EU Agenda examines how Ireland can position its national life sciences strategy in the context of the European Commission's 2025 Strategy for European Life Sciences and other new EU initiatives. Drawing on national and EU-level experience, panellists discuss key developments in EU life sciences policy and what Europe is doing to strengthen its competitiveness, research capacity, and innovation ecosystem. The event will also explore how Ireland can secure and strengthen its own role as a key player in Europe's life sciences landscape by aligning its policy ambitions with emerging European trends. This event is organised by the Institute of International and European Affairs in partnership with Johnson & Johnson. Panellists: Pilar Aguar Fernandez, Director at People: Health and Society at DG Research and Innovation, European Commission Anouk de Vroey, Head of Government Affairs & Policy at Johnson & Johnson EMEA Muiris O'Connor, Assistant Secretary at Department of Health, Head of Research & Development and Health Analytics Darrin Morrissey, CEO of NIBRT National Institute for Bioprocessing Research and Training Frances Fitzgerald, Former MEP and Tánaiste (Moderator) Ireland is home to a high-performing life sciences industry, offering major opportunities for both economic development and public health. Unlike other European countries, however, Ireland does not have a holistic vision for the future of the sector. This is set to change, as the Government has promised to develop a national life sciences strategy. Other European countries have already adopted ambitious strategies to secure the future of the industry and unleash its benefits, coordinating policy across a range of areas from enterprise and investment to research and healthcare. Across the European Union, Member States are aligning national policy with broader EU ambitions for health innovation, research, and industrial resilience. Under initiatives such as Horizon Europe, the European Health Union, and EU4Health, the EU is already providing an increasingly integrated vision. In addition to this, this summer, the EU Life Sciences Strategy has been adopted by the Commission, while a new Critical Medicines Act and Biotech Act are expected soon. What will these new policies mean for Europe? And how should they be reflected in Ireland's national strategy?

Back in April, a company called Colossal Biosciences announced that they had brought dire wolves — ancient canines of Game of Thrones fame — back from extinction. The internet went wild. But while some media outlets proclaimed the return of a long-gone species, many scientists shot back on social media that these weren't really dire wolves, they were just genetically engineered grey wolves. Suddenly everybody had an opinion on what de-extinction is, what it is not, and whether or not we should be doing things like this in the first place. In this episode, we talk to scientists who have been working in this area for a while, and they not only share their thoughts on these wolves — they completely change our understanding of the term “de-extinction.”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of EisnerAmper's Private Equity Dealbook, Elana Margulies-Snyderman, Director, Publications, speaks with Robert Esposito, Managing Director in the firm's Transaction Advisory Services Group. Bob shares his outlook for dealmaking in the life sciences industry, including the opportunities, challenges and due diligence considerations. He also discusses what private equity managers look for in the buy-side process to better ensure that both a mutually beneficial and efficient transaction can be consummated in today's economic and transaction market environment. The conversation dives deep into life sciences M&A, private equity dealmaking, and healthcare investment strategies. Whether you're an investor, entrepreneur, or advisor, you'll gain insights into how deals are structured, what risks matter most, and where the biggest opportunities lie in 2025.

In der aktuellen Folge sprechen Alois Krtil und Oliver Rößling mit Prof. Hauke Heekeren, Arzt, Neurowissenschaftler und seit 2022 Präsident der Universität Hamburg. Ein Gespräch über Hamburgs wissenschaftlichen Aufbruch, die Rolle von Vernetzung und Transfer – und darüber, wie Künstliche Intelligenz Lehre, Forschung und Verwaltung verändert.Hamburg hat in den vergangenen Jahren deutlich aufgeholt. Die Universität Hamburg konnte ihre vier Exzellenzcluster erfolgreich in die nächste Förderperiode bringen – von Astrophysik und Photon Science bis Klima und Schriftartefakte. Zusätzlich gewann die TU Hamburg mit BlueMat ein weiteres Cluster im Bereich Materialforschung. Zusammen ergibt das fünf Exzellenzcluster in der Metropolregion und damit ein starkes Signal für den Standort.Heekeren betont besonders die Vernetzung als Standortvorteil: Hamburg sei groß genug für Spitzenforschung, aber klein genug, um alle relevanten Akteure an einen Tisch zu bekommen. Beispielhaft steht dafür PIER, die Partnerschaft von Universität Hamburg und DESY, und ihr Ausbau zu PIER PLUS, wo 23 Hochschulen und Forschungseinrichtungen gemeinsam Strategien für Forschung, Transfer und Karrierewege entwickeln.Beim Thema Transfer verfolgt die Universität einen breiten Ansatz: von Politikberatung und Bürgerdialog bis zu Start-ups und Ausgründungen. Ein aktuelles Leuchtturmprojekt ist die Initiative Impossible Founders, die im Rahmen der bundesweiten „Startup Factories“ gefördert wird. Mehr als 50 Millionen Euro von Bund, Stiftungen und Unternehmen fließen in eine Gründungsfabrik für Deep-Tech-Spin-offs, die ab Herbst 2025 operativ startet. Mit Arik Willner wurde ein erfahrener Transfermanager als CEO gewonnen.Ein weiteres Zukunftsprojekt ist die Science City Bahrenfeld: ein kompletter Stadtteil, in dem Leben, Forschen, Studieren und Gründen zusammengeführt werden. Rund um DESY, eines der führenden Forschungszentren für Photon- und Teilchenphysik, entsteht Infrastruktur, die von Quantenforschung bis zu Life Sciences reicht – inklusive gemeinsamer Institute der Universität.Ein zentrales Thema ist die Künstliche Intelligenz. Die Universität Hamburg hat früh eine eigene, datenschutzkonforme Variante von ChatGPT eingeführt. Heekeren plädiert für einen reflektierten Einsatz: KI könne Prozesse beschleunigen und Ideen anstoßen, dürfe aber wissenschaftliche Urheberschaft und kritisches Denken nicht ersetzen. Als Beispiel nennt er die automatisierte Prüfung internationaler Bewerbungsunterlagen – eine Lösung, die aus Kooperationen mit der Hamburger Hafenwirtschaft hervorging.Im Gespräch wird deutlich, dass Europa mit seinen Werten eine besondere Rolle spielen kann. Während in den USA oder China Technologien oft rein marktorientiert oder staatlich gesteuert vorangetrieben werden, setzt Heekeren auf Wissenschaftsfreiheit, kostenfreie Bildung und Interdisziplinarität als Standortvorteile. Gerade eine Volluniversität, die Natur- und Ingenieurwissenschaften mit Geistes-, Rechts- und Sozialwissenschaften verbindet, sei unverzichtbar, um Fragen nach Ethik, Recht und gesellschaftlicher Verantwortung von KI zu beantworten.Zum Schluss formuliert Heekeren drei zentrale Aufgaben für Hamburgs Wissenschaftsstandort:Talente gewinnen und halten – von jungen Forschenden bis zu Spitzenkräften in Informatik und KI.Forschungstechnische Infrastruktur ausbauen, insbesondere große GPU-Cluster.Transfer und Karrierewege beschleunigen, um wissenschaftliche Erkenntnisse schneller in die Anwendung zu bringen.Die Folge zeigt Hamburg als Standort mit klarer Richtung: Fünf Exzellenzcluster, enge Vernetzung, eine entstehende Science City und eine Universität, die KI nicht nur nutzt, sondern gestaltet. Heekerens Botschaft: Vernetzung, Verantwortung, Geschwindigkeit – wenn diese Faktoren zusammenkommen, wird aus Forschung gesellschaftlich spürbarer Fortschritt.

"Every community has different values, and every community should have different choices. And that's why local food is so important so that local communities and local farmers can decide what's most important to them and how they want to connect the people who grow our food with the people who are seeking nourishment." —Andy Naja-Riese "The health of our Farmers Market is really dependent upon the health of our farmers." —Tanner Keys   Wonder why local food sometimes costs more, or if it's really worth the effort to shop there? The real story behind farmers' markets is more complicated—and more important—than you might think. Andy Naja-Riese, CEO of the Agricultural Institute of Marin, and Tanner Keys, Cooperative Agreement Manager for the Islands of Remote Areas Regional Food Business Center, have spent years on the front lines of food access. Their work in California and Hawaii gives them a unique view on what it takes to make local food affordable, how certification and regulations shape what you see at the market, and why these markets matter for everyone. Listen in for honest talk about food prices, local farming, organic rules, food as medicine, and how farmers' markets are working to make healthy food available to all. You'll get practical insights, real solutions, and a fresh look at what's possible in your own community. Meet Andy: Andy Naja-Riese brings 17 years of experience in community food systems, public health, and food equity programs & policy. As Chief Executive Officer, he leads AIM's major programs, partnerships, strategic planning, advocacy, and fundraising, including a capital campaign for AIM's Center for Food and Agriculture in collaboration with AIM's Board of Directors. Andy joined AIM in 2018 after spending 10 years working for the Federal government, including the U.S. Department of Agriculture's Food and Nutrition Service.  Andy is currently the Co-Chair of the Marin County Healthy Eating Active Living (HEAL) Collaborative, serves on the Steering Committees of the Marin Carbon Project and Marin Community Health Improvement Plan, sits on the National Farm to School Network's Advisory Board, and represents AIM on the California Food and Farming Network & Food and Farm Resilience Coalition. He received the 2022 CVNL Heart of Marin Award for Excellence in Leadership and the 2023 Farmers Market Champion of the Year award from CAFF. He earned his master's degree from the T.H. Chan Harvard School of Public Health and his bachelor's degree from Cornell University's College of Agriculture and Life Sciences.  He lives with his husband and dog in Sonoma, where he enjoys backyard gardening, cooking farmers market hauls, eating bagels, and enjoying Northern California's natural beauty Website Facebook X Instagram LinkedIn YouTube   Meet Tanner: Tanner Keys grew up in an agricultural community & lifestyle that has instilled a passion for food & land. He has served in various roles with the Hawaiʻi Good Food Alliance (HGFA) beginning in 2022, helping the organization in its beginning years and later leading a project of HGFA, the Hawaiʻi Farmers Market Association. Before that, he served as the Team Leader to the FoodCorps Inc., an AmeriCorps program, from 2019 to 2021. Tanner has a B.S. in Business Administration from the University of Oregon, and it was his service in the Peace Corps (Timor-Leste ʻ16-ʻ18) that led him back to the path of supporting agriculture & food security. LinkedIn Connect with Hawai'i Good Food Alliance Website Instagram Facebook   Connect with NextGen Purpose: Website Facebook Instagram LinkedIn YouTube   Episode Highlights: 01:16 Geography and Food Access: How Location Changes Everything 06:13 Comparing Coasts: East vs West Market Experiences  10:38 Organic vs Certified— What “Certified” Really Means  16:53 Hawaii and California's Diversity  23:40 Making Markets Accessible  27:55 Permanent Market Dreams: Building for the Future  33:57 Are Farmers' Markets Expensive? The Real Price of Local Food   Resources: Podcast S5 Ep 27: AIM— Preserving the Farmer's Market for Everyone with Andy Naja-Riese Part 2S7 Ep1: Boosting a Healthy, Accessible Local Farm-to-Table Revolution with Andy Naja-Riese Part 2

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Meg speaks to Ilya Burkov, the Global Head of Healthcare & Lifesciences Growth at Nebius AI.Nebius AI's goal is simple: to provide the cloud infrastructure that will be the groundwork of the AI revolution we can all see happening in front of us. Nebius' suite of tools helps life science companies gather data and then train, fine-tune and launch their AI models into the world.Ilya's role is to oversee and drive the adoption of this cloud AI technology within the life science and healthcare sectors, placing him at the cutting edge of this next wave of industry change. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of the Econ Dev Show, Dane Carlson sits down with Kathleen Coviello, Chief Economic Transformation Officer at the New Jersey Economic Development Authority, to explore how New Jersey is reshaping its economic future. Kathleen discusses the state's targeted approach to building industries where it has a competitive edge—from film and digital media to life sciences, clean energy, and AI. She shares insights into innovative initiatives like film-ready certified towns, programs that turn company losses into cash, and the ambitious Evergreen Fund designed to attract venture capital and corporate engagement. Along the way, Kathleen highlights both the opportunities and challenges facing New Jersey, including housing affordability and talent retention, while also offering a candid look at her own journey from venture banking to two decades in public service. Like this show? Please leave us a review here (https://econdevshow.com/rate-this-podcast/) — even one sentence helps! Special Guest: Kathleen Coviello.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kaan-Fabian Kekec, Partner in Healthcare and Life Sciences at Simon-Kucher. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kaan, covering: Being on the sunny side of consulting, and helping clients unlock growth. What makes a key strategic partnership both from a CDMO, and a sponsor perspective. The taboo subject of pricing and how it can be used to help unlock commercial positioning, and excellence. Common mistakes in BD teams, and the importance of value positioning. The hottest segments in the market right now, and some of the competitive drivers in today's market. Kaan leads the firm's Healthcare B2B and Pharma Services business globally, encompassing CDMOs, CROs, bioprocessing solutions, drug delivery, packaging, and more. He specializes in delivering end-to-end commercial strategies for CDMOs, advising on growth initiatives and supporting clients throughout the entire lead-to-deal process—from marketing and sales to proposal management and deal optimization. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.  Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Brief Encounters, Richard is joined by Glen Walters, Head of Early Stage Tech and Life Sciences at HSBC Innovation Banking.They cover:Why “why you're raising” matters as much as “how much”What an investor-ready data room should includeHow legal teams can act as business partnersUnderstanding market standards in term sheetsTrends in valuations, structures, and fundraising termsWhy financial modeling and profitability are essential for startupsA practical guide for founders navigating early-stage fundraising.

Many supplements claim to “boost” your immune system. Now, we all want to avoid getting sick during the winter months, but do any of these products really work? And is trying to “boost” your immune system even a good idea? Jonathan speaks with Professor Daniel M. Davis, MBE — a leading expert on immunology and Head of Life Sciences at Imperial College London. Daniel has published 145 scientific papers, authored four best-selling science books, and spent 25 years researching how our immune system works. He even helped discover the immune synapse, a breakthrough that changed our understanding of immunity. Daniel explains how your immune system really works, why it's connected to mental health, and how it can even detect cancer cells. He also clears up common myths and shares what genuinely helps keep your immune system strong through the winter months — and what won't make a difference. By the end of the episode, you'll know the practical, science-backed steps you can take to reduce your risk of colds and flu this winter without wasting money on products that don't deliver. Unwrap the truth about your food

In this episode, Seema Verma, EVP and GM of Oracle Health and Life Sciences, discusses Oracle's vision for transforming healthcare through AI, interoperability, and next-generation EHR technology. She shares insights on reducing administrative costs, advancing clinical research, improving prior authorization, and strengthening cybersecurity to create a more efficient and patient-centered system.This episode is sponsored by Oracle.

In this episode of Tiny Show and Tell Us, we talk about cute woolly mammoth mice and debate whether research to bring back extinct species (or their genes) is ethical or a good use of money and time. Then we discuss the best way to remove microplastics from water. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Looking for the secret sauce behind building a top-tier recruiting agency in a hyper-competitive market? Want to combine heart-driven recruiting with razor-sharp business strategy? In this must-listen episode, Benjamin Mena sits down with Cari Kraft—legendary leader and top biller at Jacobs Management Group—to reveal how niching down and leading with integrity can skyrocket your recruiting business.  

Join us this week for The Tech Leaders Podcast, where Gareth sits down with Chris Moore, European President at Veeva Systems. Chris talks about the impact AI will have on software development and data security, how technology has transformed the life sciences industry, and the long-term implications of Covid on drug development.On this episode, Chris and Gareth discuss how Chris helped make Veeva Europe more European, the importance of understanding the opportunities and threats associated with new technologies, and why the Y2K bug was a beautiful anti-climax.Timestamps:ICI, Kinesis and PWC (3:40)IBM, EY and living abroad (10:28)Making Veeva Europe more European (17:30)The impact of Covid on drug development (29:05)The evolution of the CIO (33:00)AI: Hopes, fears and the impact on software development and pharma (36:33)Advice for 21-year-old Chris (51:46)https://www.bedigitaluk.com/

In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Melissa Wu, co-founder and CEO of Seeding Labs, a nonprofit that's redefining global scientific access. Dr. Wu shares the inspiring story of how Seeding Labs helps institutions in developing nations build research infrastructure by redistributing surplus laboratory equipment from partners like Thermo Fisher Scientific.With an innovative model that connects equipment donors in the global North with universities and institutes across Africa, Asia, and Latin America, Seeding Labs enables groundbreaking science in places where opportunity is limited but talent is abundant. Dr. Wu highlights examples like the Malawi University of Science and Technology, whose graduates are now staffing the country's first hospital microbiology labs, and a Beninese research team using donated PCR equipment to improve the yield of indigenous crops like the miracle berry.More than a logistics operation, Seeding Labs is also fostering scientific networks, reversing brain drain, and giving researchers confidence, courage, and agency. Dr. Wu offers a compelling vision of an equitable global scientific ecosystem, and shares how listeners can get involved—whether by donating equipment, funds, or simply spreading the word. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn this episode, we will interview Dr. Thomas Cavaliere, the current Dean of the Rowan Virtua School of Osteopathic Medicine. Dr. Cavaliere graduated from the Des Moines University College of Osteopathic Medicine, following which he completed an internal medicine residency at Thomas Jefferson University Hospital. Under his leadership, the Rowan Virtua School of Osteopathic Medicine has been named one of the best medical schools in the country for primary care and geriatric medical education. Dr. Cavalierey has also recently been selected to serve as the inaugural Senior Vice Provost of the Virtua Health College of Medicine and Life Sciences, as well as the Chief Academic Officer for the Virtua Health System. It is an honor to interview such an accomplished physician, and we believe his perspectives are valuable for everyone from pre-medical students to attending physicians. Dr. Cavaliere will discuss the advantages of pursuing a career in academic medicine, emphasizing the opportunity to combine clinical practice with teaching and research, and the fulfillment of caring for patients while training the next generation of physicians. We know you will love this episode.

As clinical research becomes increasingly digital, the legal and compliance landscape is shifting. Hal Porter, Director of Consulting Services, Clearwater, speaks with Dianne Bourque, Partner, Holland & Knight LLP, about the legal, regulatory, and ethical considerations when clinical trial data is compromised. They discuss issues related to regulatory frameworks and legal obligations, risk exposure and liability, impacts of a breach that go beyond privacy, cross border data and transfer risks, and mitigating the risk and fallout of data breaches in clinical trials. Sponsored by Clearwater.Watch this episode: https://youtu.be/XwtZXXGmLx4Learn more about Clearwater: https://clearwatersecurity.com/ Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Jan de Kerpel is Manager Director en Hoofd Life Sciences bij Van Lanschot Kempen.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adam Siebert, Managing Director and Partner at L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: Adam's journey from academic to commercial, and what helped him transition into 'life science enablers". How pandemic demand has left our sector with a huge over capacity issue and market imbalance. Some positive signals for the second half of 2025 after a period of geopolitical chaos, and a bumpy rollercoaster. Even thought biotech funding has largely returned... how decreasing clinical trials, a shifting of therapeutic focus, and the concentration of investments on fewer, higher value deals is impacting pharma services. The value of building a reputation in one in-demand modality area before extending into other modalities. And why the CDMO is at an inflexion point... Adam is a Managing Director and Partner in L.E.K. Consulting's New York office and a member of the Life Sciences practice. He has been with L.E.K. for over eight years, and has experience across diagnostics and research tools, bioprocessing and pharma services, and emerging, mid-cap and large pharma. Adam has helped a number of clients in the life sciences industry with growth strategy, life cycle management, portfolio optimization and M&A projects. Adam holds a Bachelor of Science from Boston College and a Ph.D. from the Perelman School of Medicine at the University of Pennsylvania.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

To mark our 200th episode, we are taking you into Space to discover the benefits of microgravity for health and medical research and its real-world applications. Can we use space technology to advance medical discoveries to improve health here on earth? And should we be doing more to connect our life science sector innovators into Australia's space research sector?We meet leading Australian superstars working at the intersection of space and health technologies at MTPConnect SA's Insights Series event “What's Your Place in Space', celebrating Australian Space Week in Adelaide.Australia's first astronaut, Katherine Bennell-Pegg, Director of Space Technology at the Australian Space Agency shares her view on why space matters, and the role of astronauts on the International Space Station as scientists in space. She reveals how biotech research in space using microgravity is revolutionising pharmaceutical development and unlocking treatments for cancer here on Earth.Aerospace medicine specialist Dr Gordon Cable from Human Aerospace, is working on a spacesuit design program, developing compression garments that "trick" the body into thinking gravity exists, with applications for burns, lymphedema and post-surgical recovery. Dr Richard Harvey from the ARC Centre of Excellence in Plants for Space explains how the international research consortium is engineering smart plants in space labs, that operate as programmable biological factories for biomolecule synthesis, to produce pharmaceuticals, including compounds that protect against radiation and improve cancer therapies. And Tiffany Sharp from Cambrian Defence and Space discusses launching medical research into space on a rocket in the Arctic circle - looking into the gut microbiome which shows how certain bacteria affecting anxiety and depression decline in microgravity, offering insights for mental health treatments.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA's ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O'Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library 

This week, we went to the doctor. Oz speaks with Dr. Matthew Lungren, the Chief Scientific Officer for Microsoft Health & Life Sciences, who co-authored a study showing that AI diagnosed complex medical cases four times faster than human doctors. Dr. Lungren walked us through how multiple AI agents worked together to generate their diagnoses, what that means for the future of medicine—and how human doctors and AI could collaborate to build a more democratized healthcare system.See omnystudio.com/listener for privacy information.

In this episode of Tiny Show and Tell Us, we talk about a new and exciting biodegradable polymer that seems to outperform commercial super glues. Then we discuss a compound called sulfur hexafluoride (SF6) that is used in high voltage equipment. Not only is SF6 a potent greenhouse gas, if you breathe it in it has the opposite effect of helium — it makes your voice deep. But it can also lead to asphyxiation so you should not breathe it in. We repeat: do not breathe this gas in. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The new season of Business Class News's Race to the Start Line podcast launched with a conversation that was both deeply personal and profoundly forward-looking. Host Karl Woolfenden sat down with two leaders from Caris Life Sciences—Dr. David Spetzler, President and Chief Scientific Officer, and Dr. James Hamrick, Chairman of the Caris Precision Oncology Alliance —for a discussion on how Caris is transforming the future of cancer care. Woolfenden framed the conversation with personal reflections, sharing how recent losses in his own circle to cancer heightened his awareness of the need for innovation in oncology. “It tightened my awareness,” he said, “of how important it is to spotlight the companies and individuals driving meaningful progress.” Tackling the Complexity of Cancer Caris Life Sciences is a leader in molecular profiling and precision medicine, advancing how oncologists understand and treat cancer. Dr. Spetzler emphasized just how complicated this mission is: “Yeah, so I think what the patents demonstrate is that we're really on the cutting edge of trying to understand cancer. And the complexity of cancer is really quite staggering, because there are no two diseases that are the same.” He explained that Caris has built one of the world's largest datasets in cancer biology. “One of the things that we've been able to do is amass an enormous data set. We're approaching having profiled a million patients, and one of the great advantages that gives us is we can start to understand—from previous patients—new patients' status, and direct them towards the better drugs that are going to help them live longer.” From Science to the Patient Bedside Where Spetzler focused on the science, Dr. James Hamrick provided a clinical lens on the company's work. He reflected on his journey as both a practicing oncologist and now a leader at Caris. “The founder of Caris, and Dr. Spetzler who has been there since 2009, was always that connection point between the science and the patient. And that's where I focus—making sure what we're doing actually makes a difference in the clinic.” Hamrick highlighted the importance of ensuring that breakthroughs aren't confined to research institutions but are accessible to patients everywhere: “Too often, patients in community hospitals don't benefit from the latest advancements available at large academic medical centers. At Caris, we're working to close that gap.” Humanizing the Science The conversation underscored the human stakes of the work. Both leaders emphasized that the mission isn't just about data or discovery—it's about outcomes. Dr. Spetzler summed it up: “Science is only as valuable as the difference it makes in the real world. That's what drives us every day.” Scaling Innovation for the Future For Caris, growth means more than company expansion—it means scaling the reach of its technology so that physicians everywhere have the tools to personalize cancer care. This, Woolfenden pointed out, is a different kind of “race to the start line”: one where the finish line is measured in lives saved and futures extended. As the first episode in the series, the dialogue with Caris Life Sciences set a high standard for Race to the Start Line. It showcased how innovation, when combined with purpose, can shape industries—and in this case, save lives. 

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's Cloud Wars Minute, I explain how Oracle is transforming healthcare with its AI-driven, cloud-native EHR, setting a bold path toward intelligent care.Highlights00:02 — Oracle has introduced an updated version of Oracle Health EHR, or Electronic Health Record, for ambulatory providers in the U.S., built on Oracle Cloud Infrastructure. The new system features native AI agents that operate together as an orchestrated system for maximum process efficiency.00:29 — The new Oracle Health EHR, was designed in collaboration with frontline providers and delivers the services that they require in a manner that's most useful to them. For example, it features personalized, streamlined workflows. In 2026, Oracle plans to enhance the system to include acute care, further expanding the reach of this groundbreaking technology.00:50 — Now, this represents a major leap forward for healthcare providers, and Oracle is right to focus significant efforts in this direction, enabling clinicians to cut through the administrative burdens of the healthcare industry. Identified as one of the first major use cases for generative AI, it remains a priority, and Oracle is certainly thinking big in this area.01:13 — In fact, Seema Verma, Executive Vice President and General Manager of Oracle Health and Life Sciences, said the following: "When Oracle committed to transforming the healthcare industry, we knew we had to start with the EHR." Note the commitment to not just supporting, but "transforming" the healthcare industry. Visit Cloud Wars for more.

Matters Microbial #104: Antibiotic “Tolerance” and Biofilms August 21, 2025 Today, Dr. Boo Shan Tseng, Associate Professor at the University of Nevada Las Vegas School of Life Sciences, joins the #QualityQuorum to discuss bacterial biofilms and antibiotic tolerance.  Host: Mark O. Martin Guest: Boo Shan Tseng Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A video overview of biofilms. A comprehensive review article on biofilms. An article describing the impact biofilms have on disease. An article describing the impact of biofilms on implanted medical devices. A link to the Center for Biofilm Engineering at Montana State University that has MANY links of interest. An overview of biofilm development. An overview of confocal laser microscopy. Studying biofilms in flow cells. An article about the role proteins play in biofilm formation, which intersects with the Tseng group's research. The technique of single cell RNA seq. The technique of mRNA-FISH. An article about porins in bacteria, and how that can relate to antibiotic resistance. An article by Dr. Tseng and coworkers on the eDNA and biofilms discussed today. A lovely video of Dr. Tseng talking about the research she and her colleagues carry out in the laboratory. Dr. Tseng's biography from the American Society for Microbiology. Dr. Tseng's laboratory group website with wonderful links and images. Dr. Tseng's faculty website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Jim talks with Lawrence Cahoone about the ideas in his book The Orders of Nature: An Introduction to the Philosophy of Complex Systems for the Life Sciences. They discuss how Cahoone's naturalist philosophy bridges multiple philosophical domains, his distinctive use of emergence theory borrowed from William Wimsatt, the concept of "no simples" in objective relativism, the role of Prigogine in emergence theory, Cahoone's self-taught approach to understanding physics and science, fallibilist and local metaphysics, Columbian naturalism and its rejection of the supernatural, the relationship between objects and their contexts, scientific explanations of relativity and quantum mechanics, and much more. Episode Transcript The Orders of Nature: An Introduction to the Philosophy of Complex Systems for the Life Sciences, by Lawrence Cahoone The Emergence of Value: Human Norms in a Natural World, by Lawrence Cahoone The Feynman Lectures on Physics, by Richard Feynman Lawrence Cahoone graduated with a Ph.D. in Philosophy at Stony Brook University in 1985. Cahoone's areas of specialization are American Philosophy, Continental Philosophy, Social and Political Philosophy, Philosophy of Culture, Metaphysics and Natural Science and Modernism and Postmodernism. Since 2000, Cahoone has taught at Holy Cross and is now currently an Emeritus Professor of Philosophy at Holy Cross. He has also written and published seven books in his career, including The Emergence of Value, The Orders of Nature, and Cultural Revolutions.

After some years developing websites and interactive and digital marketing projects, Guillem joined Merck in 2009, and he has been always related to digital marketing projects on the business side. Since 2020 Guillem has been driving the Social Selling initiative for Merck Life Science, focusing on Social Scouting with LinkedIn Sales Navigator, Social Listening and Employee Advocacy, to help Sales teams be more effective by using social channels to uncover new business opportunities. His work with using Chat CPT to support employee content has been truly inspiring with some great results. Folllow him on Linkedin for more https://www.linkedin.com/in/guillemcardenal/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Hamid Ghanadan, CEO at LINUS, reports on their recent State of Science research that tracks scientists' sentiment, funding expectations, and barriers to their work. Key findings reveal that the politicization of science and erosion of public trust in science threaten to slow innovation rates and negatively impact public access to accurate information. The survey also shows a direct negative impact on scientists' morale, job satisfaction, and creativity. We talk about: The growing perception of the public that science is not real Sources of public distrust of scientific information When scientists become politically active  Need for more direct communication from the scientists and life science leaders to make complex topics more understandable and relevant Opportunity for researchers, institutions, vendors, and advocacy groups to recognize these issues and take responsibility to improve the communication of accurate health and medical information to a broader audience #TheLINUSGroup #Scientists #MedicalResearchers #PublicTrust #PoliticizationofScience #HealthcareInformation #MedicalInformation  TheLINUSGroup.com

An estimated 132 million babies were born across the globe last year — really just a drop in the bucket when you think about the over 100 billion babies born since modern humans first lived on Earth 200,000 years ago. And until very recently we had few tools to understand how they were doing in the womb, how they would fare in the days after birth, and how a pregnant person would change physically and mentally not just during pregnancy but in the months and years that followed. Things have changed dramatically, particularly over the last decade, in terms of the care and technology that's available preconception, during pregnancy, and post-birth. But there is still so much we don't know about these time periods, both for baby and mom, and many a black box remains. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of Digital Squared: From the Archives, we're revisiting a conversation with Ed Marx, Chief Digital Officer for Tech Mahindra Health and Life Sciences and formerly the CIO at Cleveland Clinic and NYC Health & Hospitals. Ed is full of enthusiasm, curiosity and drive, and he has used those tools to expand his own horizons and to act as catalyst to define the role of the post-modern CIO for the healthcare industry.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“More technology, more life science and healthcare:” Scott Sperling believes these are what will fuel the future. He also sees opportunities in logistics and thinks more businesses will “fundamentally tweak” their models with technology to become more efficient and prosperous. On the Fed, he says the best option is a 25 basis point rate cut in September. He also brings the case that the Fed is losing control over the 10-year.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

  The Garden State, called the “medicine chest” to the world, continues to show robust activity with life sciences firms accounting for nearly 30% of all Q2 leasing activity. Greg Slabodkin   Read by Brittany Duncan    https://www.pharmamanufacturing.com/all-articles/article/55308250/new-jersey-remains-hot-life-sciences-hub-despite-macroeconomic-funding-headwinds 

Welcome to Automating Quality, the life sciences–focused show that bridges the gap between automation and quality management. In today's episode, our host Philippe welcomes Jim Ferguson, President and Owner of NuQual Consulting. With over 25 years of experience in the life sciences industry, Jim brings deep expertise in supplier quality and compliance. Together, they dive into the world of internal audits — how they can be used not only to maintain compliance but also to proactively identify and resolve potential observations before a regulatory inspection takes place.   Key Takeaways 01:22 Introducing today's guest, Jim Ferguson from NuQual Consulting 02:18 What quality-focused events has Jim been attending lately? 04:30 How can internal audits help organizations prepare for regulatory inspections or other types of audits? 07:25 What is the value of outsourcing internal audits? 08:35 How can companies ensure that audit findings actually lead to meaningful changes? 12:57 What does a strong response to internal audit findings look like? 17:30 What are some common pitfalls organizations tend to overlook during internal audits?   Contact Jim at https://nuqualconsulting.ca/ Contact us at solabs-podcast@solabs.com

McAndrew Rudisill, Board Chair for ETHZilla, joined me to discuss ETHZilla's Ethereum corporate treasury.Topics:- 180 Life Sciences Corp rebrand to ETHZilla - Choosing Ethereum as a treasury asset - Ethereum staking and DeFi - Crypto Treasury strategy risks - Crypto Legislation & Market Outlook 

Jack Moody is back hosting this week and we catch up on the racing from the weekend. We revisit our interview with Dr. Philip Hurst, former middle-distance runner and current academic from the School of Psychology and Life Sciences at Canterbury University. We discuss the intriguing world of the 'placebo effect', its negative counterpart - the 'nocebo effect' and their impact on sports performance. Drawing from his research and experience, Dr. Hurst shares the significance of these effects in the medical world and how they have the potential to shape athlete performance. (0:00:00) – Calling in from Prague (0:04:20) – Prague – a wetsuit race (0:06:41) – Charlotte McLauchlan study  (0:09:08) – IM703 Melbourne competition                        (0:11:12) – Racing from the weekend (0:24:22) – IM703 Hradec-Kralove (Prague) (0:43:04) – Dr Philip Hurst LINKS: Follow Jack Moody on Instagram at https://www.instagram.com/jacktmoody/ Dr Philip Hurst's review “The Placebo and Nocebo effect on sports performance: A systematic review” at https://pubmed.ncbi.nlm.nih.gov/31414966/ Follow Dr Philip Hurst on Twitter at https://twitter.com/Phil_Hurst1 IRONMAN 70.3 Hradec-Kralove (Prague) at https://www.ironman.com/races/im703-hradec-kralove Charlotte McLauchlan can be contacted by email at cmcl126@aucklanduni.ac.nz Fitter Radio Episode 613 – Interview with Charlotte McLauchlan at https://www.fitter.co.nz/fitter-radio/2025/4/12/episode-613-confidence-nutrition-and-the-mind Plasmaide at https://plasmaide.com/

Melissa Sleeper is a National Board Certified Teacher currently teaching Life Science and Space Science at Holy Trinity Episcopal Academy in Melbourne, Florida. A career changer, Melissa worked as an Agriculture Economist/Statistician setting up crop reporting services and running rural household surveys. She lived and taught in both public and private schools in Morocco, Egypt, Grenada, Barbados, Bolivia, and Nicaragua in addition to her extensive work here in the States. Melissa has the unique experience of being able to say she has taught at every grade level from pre-K to adult.. Melissa an active member of the National Science Teaching Association, The AIAA and has served on, among others, the Aerospace Advisory Board and National Middle Level Science Teachers Association. Her passion for space education was flamed when she was selected an Educator Ambassador for NASA's MAVEN Mission. We are grateful to know such a passionate STEM educator and we know you will appreciate Melissa as much as we do. SmallSat Education Conference:

Building Maryland's BioHealth Future: Maryland Commerce's Stefanie Trop on Growing the Life Sciences Sector In this episode of BioTalk with Rich Bendis, Stefanie Trop, Ph.D., Director of Life Sciences at the Maryland Department of Commerce joins the conversation to discuss Maryland's position as a leading life sciences hub. Stefanie shares how the Department of Commerce supports company attraction and growth through programs like Global Gateway, and how it's amplifying the state's recent #3 biopharma hub ranking. The discussion also explores Maryland's unique ecosystem, including the work of the Governor's Life Sciences Advisory Board, the state's leadership in computational health, and the importance of industry collaboration during BioHealth Capital Region Week. Editing and post-production work for this episode was provided by The Podcast Consultant. Dr. Stefanie Trop brings a unique blend of hands-on scientific expertise and high-level strategic insight. With a Ph.D. in Molecular Microbiology and Immunology, she has worked at the ground level in immunology, clinical trials, and vaccine development, while also driving growth through scientific partnerships and business development. Her deep understanding of the science and passion for problem solving guides her ability to build effective collaborations that advance both innovation and commercial success. At the Maryland Department of Commerce, Stefanie works to connect Maryland's life sciences companies with national and global resources, expanding the industry's impact at home and globally. In current and prior roles, she bridges communication gaps between scientific and business teams, ensuring that customer needs translate into innovative products and business wins.

As AI becomes deeply embedded in every industry, building AI systems that are secure, responsible, and privacy-centric is more crucial than ever. But where do you begin? At the strategy level? Design? Or implementation? How do organizations tackle the challenges of AI risks, data governance, and compliance while keeping pace with innovation?Join us for an insightful conversation with Punit Bhatia and Santosh Kaveti, CEO of Pro Arch, as we explore the evolving landscape of responsible AI, key foundational steps, and the practical approaches to secure AI deployment.If you're looking to understand how to build AI systems that are not only innovative but also secure and trustworthy, this episode is for you!KEY CONVERSION 00:01:58 Responsible AI 00:04:30 AI Strategy 00:11:43 Role of standards and Approach 00:15:35 Good practices of Data Governance 00:19:55 AI Talent 00:23:10 Pro Arch Role in costumers 00:25:00 Contact Information of Santosh  ABOUT GUEST Santosh Kaveti is CEO & Founder at Proarch. With over 18 years of experience as a technologist, entrepreneur, investor, and advisor, Santosh Kaveti is the CEO and Founder of ProArch, a purpose-driven enterprise that accelerates value and increases resilience for its clients with consulting and technology services, enabled by cloud, guided by data, fueled by apps, and secured by design. Santosh's vision and leadership have propelled ProArch to become a dominant force in key industry verticals, such as Energy, Healthcare & Lifesciences, and Manufacturing, where he leverages his expertise in manufacturing process improvement, mentoring, and consulting. Operationalizing AI: From Strategy to Execution Navigating AI Risks: Ensuring Security and Compliance Prioritizing AI Initiatives: Aligning with Business Goals Attracting and Retaining Top AI Talent Integrating AI into Core Business Functions The Data Foundation: Governance, Quality, and Culture in AI  Santosh's journey is marked by resilience, ambition, and self-awareness, as he has learned from his successes and failures, and continuously evolved his skills and perspective. He has traveled across 23 countries, gaining insights into the global diversity and interconnectedness of human experiences. He is passionate about blending technology with a human-centric approach and making a meaningful societal impact through his support for initiatives that uplift underprivileged children, assist disadvantaged families, and promote social awareness.Santosh's ethos extends to his investments in and mentorship of promising startups, as well as his role as the Chairman of the Board at Enhops and iV4, two ProArch companies.  ABOUT HOST Punit Bhatia is one of the leading privacy experts who works independently and has worked with professionals in over 30 countries. Punit works with business and privacy leaders to create an organization culture with high privacy awareness and compliance as a business priority. Selectively, Punit is open to mentor and coach professionals.  Punit is the author of books “Be Ready for GDPR' which was rated as the best GDPR Book, “AI & Privacy – How to Find Balance”, “Intro To GDPR”, and “Be an Effective DPO”. Punit is a global speaker who has spoken at over 30 global events. Punit is the creator and host of the FIT4PRIVACY Podcast. This podcast has been featured amongst top GDPR and privacy podcasts.  As a person, Punit is an avid thinker and believes in thinking, believing, and acting in line with one's value to have joy in life. He has developed the philosophy named ‘ABC for joy of life' which passionately shares. Punit is based out of Belgium, the heart of Europe.  RESOURCES Websites www.fit4privacy.com,www.punitbhatia.com, https://www.linkedin.com/in/santoshkaveti/ , https://www.proarch.com/  Podcast https://www.fit4privacy.com/podcast Blog https://www.fit4privacy.com/blog YouTube http://youtube.com/fit4privacy   

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Dr. Steffen Hoffmann, Managing Director of Bosch UK. Dr. Hoffmann joins Emerj Editorial Director Matthew DeMello to explore the strategic deployment of AI across industrial sectors, from manufacturing operations to internal business systems. Dr. Hoffmann shares how AI is helping manufacturers address upstream process variables to reduce defect rates and improve efficiency. He also discusses the importance of “human in the loop” oversight in regulated environments, and how Bosch's internal deployment of generative AI — starting with an HR assistant — serves as a model for cautious, business-aligned innovation. The conversation explores industrial applications of AI governance, the role of internal use cases in de-risking new technologies, and the broader cultural conversation around balancing AI's risks and rewards. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Medicine stands at the threshold of a new era, where artificial intelligence and systems biology are working hand in hand to make care more personal, predictive, and precise than ever before. AI is already improving diagnostic accuracy, automating administrative tasks, and uncovering patterns in data—like retinal scans or genomics—that humans often miss. Rather than replacing doctors, AI enhances their ability to deliver more informed, precise, and efficient care. At the same time, individuals are gaining tools—from at-home diagnostics to wearable biosensors—that empower them to track and optimize their own health. This shift marks a move from reactive, disease-centered care to a proactive, data-driven model of scientific wellness. In this episode, I talk with Dr. Eric Topol, Dr. Nathan Price, Dr. Leroy Hood, Dr. Vijay Pande, and Daisy Wolf about how artificial intelligence, personalized data, and wearable technology are converging to radically transform medicine. Dr. Eric Topol is Executive Vice President of Scripps Research and founder/director of its Translational Institute, recognized as one of the top 10 most cited researchers in medicine with over 1,300 publications. A cardiologist and author of several bestselling books on the future of medicine, he leads major NIH grants in precision medicine and shares cutting-edge biomedical insights through his Ground Truths newsletter and podcast. Dr. Nathan Price is Chief Scientific Officer at Thorne HealthTech, author of The Age of Scientific Wellness, and a National Academy of Medicine Emerging Leader. He also serves on the Board on Life Sciences for the National Academies and is Affiliate Faculty in Bioengineering and Computer Science at the University of Washington. Dr. Leroy Hood is CEO and founder of Phenome Health, leading the Human Phenome Initiative to sequence and track the health of one million people over 10 years. A pioneer in systems biology and co-founder of 17 biotech companies, he is a recipient of the Lasker Prize, Kyoto Prize, and National Medal of Science. Dr. Vijay Pande is a General Partner at Andreessen Horowitz and founder of a16z Bio + Health, managing over $3 billion in life sciences and healthcare investments at the intersection of biology and AI. An Adjunct Professor at Stanford, he is known for his work in computational science, earning honors like the DeLano Prize and a Guinness World Record for Folding@Home. Daisy Wolf is an investing partner at Andreessen Horowitz, specializing in healthcare AI, consumer health, and healthcare-fintech innovation. She previously worked at Meta and in various startups, holds a JD from Yale Law, an MBA from Stanford, and a BA from Yale, and is based in New York City. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Can AI Fix Our Health and Our Healthcare System? The Next Revolution In Medicine: Scientific Wellness, AI And Disease Reversal The Future of Healthcare: The Role of AI and Technology

Structural heart innovation is rewriting the future of cardiovascular care—delivering faster recoveries, better outcomes, and a new standard of precision through less invasive procedures. Breakthroughs in imaging, smarter device design, and real-time data are empowering doctors to tackle even the most complex heart conditions with unmatched accuracy. Leading this heart-health revolution is Edwards Lifesciences, a global pioneer changing the way the world treats cardiovascular disease. CEO Bernard Zovighian goes Inside the ICE House to discuss how, under his leadership, the company is breaking boundaries and saving lives - pne innovation at a time.